Expression of Ezrin, HGF and C-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder

Hepato-Gastroenterology

Volumn 59, Issue 118, 2012, Pages 1769-1775

  Yang, Leping ^a   Guo, Tanxing ^a   Jiang, Song ^a   Yang, Zhulin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

C met; Chronic cholecystitis; Ezrin; Gallbladder neoplasms; Gallbladder polyp; Hepatocyte growth factor; Immunohistochemistry

Indexed keywords

EZRIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADENOCARCINOMA; ADENOMA; ADULT; ARTICLE; CHRONIC CHOLECYSTITIS; FEMALE; GALLBLADDER CANCER; GALLBLADDER TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; CHINA; CYTOSKELETAL PROTEINS; FEMALE; GALLBLADDER; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84867707010     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11744     Document Type: Article

References (35)

1. Gatto M, Bragazzi MC, Semeraro R, et al.: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42:253-260.
2. Tucek S, Tomasek J, Halamkova J, et al.: Bile duct malignancies. Klin Onkol 2010; 23:231-241.
3. Goldin RD, Roa JC: Gallbladder cancer: a morphological and molecular update Histopathology 2009; 55:218-229.
4. Malik IA: Gallbladder cancer: current status. Expert Opin Pharmacother 2004; 5:1271-1277.
5. Oliveira AM, Ross JS, Fletcher JA: Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005; 124 Suppl:S16-28.
6. Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647:21-29.
7. Torer N, Kayaselcuk F, Nursal TZ, et al.: Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol 2007; 96:419-423. (Pubitemid 47519448)
8. Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF: Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005; 140:1184-1190.
9. Ogino W, Takeshima Y, Mori T, et al.: High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis. J Pediatr Hematol Oncol 2007; 29:435-439. (Pubitemid 47026243)
10. Bruce B, Khanna G, Ren L, et al.: Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007; 24:69-78. (Pubitemid 46669242)
11. Musial J, Sporny S, Nowicki A: Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol 2007; 58:235-243. (Pubitemid 351428300)
12. Kobel M, Gradhand E, Zeng K, et al.: Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 2006; 25:121-130. (Pubitemid 44620173)
13. Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10:201-204.
14. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S: Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 2007; 32:281-290. (Pubitemid 46439685)
15. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth F R 2002; 13:41-59. (Pubitemid 34436961)
16. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7:504-516. (Pubitemid 351767118)
17. Hara S, Nakashiro K, Goda H, Hamakawa H: Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun 2008; 370:123-128.
18. Trovato M, Vitarelli E, Grosso M, Alesci S, Benvenga S, Trimarchi F, Barresi G: Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors. Eur J Histochem 2004; 48:291-297.
19. Tsukinoki K, Yasuda M, Mori Y, Asano S, Naito H, Ota Y, Osamura RY, Watanabe Y: Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncol Rep 2004; 12:1017-1021.
20. Kawano R, Ohshima K, Karube K, Yamaguchi T, Kohno S, Suzumiya J, Kikuchi M, Tamura K: Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2004; 127:305-307. (Pubitemid 39468944)
21. Murai M, Shen X, Huang L, Carpenter WM, Lin CS, Silverman S, Regezi J, Kramer RH: Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int J Oncol 2004; 25:831-840.
22. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007; 18:76-83. (Pubitemid 46066712)
23. Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M: Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 1997; 138:423-434. (Pubitemid 27323543)
24. Jayaraman S, Jarnagin WR: Management of gallbladder cancer. Gastroenterol Clin North Am 2010; 39:331-342.
25. Yamagiwa H, Tomiyama H, Yoshimura H: Histogenesis of carcinoma of gallbladder. Histological study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori 1986; 34:475-480.
26. Dowling GP, Kelly JK: The histogenesis of adenocarcinoma of the gallbladder. Cancer 1986; 58:1702-1708. (Pubitemid 16032153)
27. Leonardo E, Valente G, Cappia S, et al.: Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994; 57:841-846. (Pubitemid 24216821)
28. Khalid H, Yasunaga A, Kishikawa M, Shibata S: Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors. Cancer 1995; 75:2571-2578.
29. Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006; 98:71-79. (Pubitemid 44050782)
30. Martin TA, Harrison G, Mansel RE, Jiang WG: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003; 46:165-186. (Pubitemid 36452345)
31. Klosek SK, Nakashiro K, Hara S, Li C, Shintani S, Hamakawa H: Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma Oncol Rep 2004; 12:293-296.
32. Nakashiro K, Hayashi Y, Oyasu R: Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 2003; 10:1149-1153.
33. Wang JW, Peng SY, Li JT, et al.: Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett 2009; 281:71-81.
34. Tanaka T, Shimura H, Sasaki T, et al.: Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther 2004; 11:431-440. (Pubitemid 38747374)
35. Sanada Y, Osada S, Tokuyama Y, et al.: Critical role of c-Met and Ki67 in progress of biliary carcinoma. Am Surg 2010; 76:372-379.